NCT07076498 is a Phase 1 clinical trial of M032 in Glioma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT07076498?

NCT07076498 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT07076498?

Interventions in NCT07076498: M032.

Is NCT07076498 still recruiting?

NCT07076498 is currently not yet recruiting. Last updated 25 February 2026.

Last reviewed 2026-02-25 · How we verify

NCT07076498

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

Not yet recruiting Phase 1 Last updated 25 February 2026

What this trial tests

Phase 1 trial testing M032 in Glioma in 20 participants. Not yet recruiting.

Timeline

1 December 2026

Primary endpoint
31 December 2029

31 December 2031

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 December 2026
Primary completion	31 December 2029
Estimated completion	31 December 2031
Sites	1 location across United States

Drugs / interventions tested

M032 — full drug profile →

Conditions studied

Glioma — all drugs for Glioma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

36 Months and older, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation.
Liu J, Ha JH, Abikenari M, Sjoholm MA, et al · · 2025 · cited 2× · PMID 41460355 · DOI 10.1007/s11060-025-05347-9
Diffuse Midline Gliomas: Clinical, Diagnostic, and Therapeutic Perspectives.
Bihari S, Yang D, Mukherji D, Haggiagi A. · · 2026 · PMID 42072474 · DOI 10.3390/biomedicines14040934
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer.
Jin S, Zhang Y, Zhou Z, Zhang Y, et al · · 2026 · PMID 41970230 · DOI 10.1002/mco2.70725
Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.
Elgehiny A, Fan AE, Frost M, He J, et al · · 2026 · PMID 41741902 · DOI 10.1007/s11060-026-05480-z

Verify or expand the search:

Other trials of M032

Trials testing the same drug.

NCT05084430 — Study of Pembrolizumab and M032 (NSC 733972) · Phase 1, PHASE2 · recruiting

Other recruiting trials for Glioma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting
NCT07405372 — Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas · recruiting
NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07527169 — A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07076498 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 25 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07076498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing